Department of Gerontology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Department of Gerontology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Exp Gerontol. 2023 Apr;174:112120. doi: 10.1016/j.exger.2023.112120. Epub 2023 Feb 18.
Sarcopenia has a significant medical and economic impact. Serum fibroblast growth factor 19 (FGF19) has recently been described as promoting muscle mass and strength, and could be an interesting marker for early diagnosis of sarcopenia and prevention of its consequences. Ultrasound is a robust non-invasive technique used to measure muscle parameters, which cannot be evaluated by usual body composition measures, but are known to be associated with muscle function. In this cross-sectional cohort study, we aimed to determine whether FGF19 levels were correlated with functional muscle tests and muscle ultrasound parameters.
Patients over 70 years old with a mobility disability risk were recruited from the cohort of the "well on your feet" mobility loss prevention program. Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older Patients 2 (EWGSOP2) criteria. We have performed functional battery tests, muscle ultrasound measures and bioimpedance spectroscopy. FGF19 levels were measured by the ELISA method.
Out of 52 patients involved (34 women, mean age 81.3 years), 30 patients were sarcopenic (15 patients with probable sarcopenia and 15 with certain sarcopenia). Sarcopenic patients were older (mean 82.8 versus 79.6 years, P = 0.033), with higher frailty Fried score (P = 0.006), lower IADL score (P = 0.008), had lower daily protein intakes (P = 0.023) and were less performant to muscle functional tests than non-sarcopenic patients. Serum FGF19 levels were negatively correlated with the SPPB score (r = 0.28; P = 0.045). FGF19 levels were correlated positively with the pennation angle (r = 0.31; P = 0.024), but negatively with muscle fiber length (r = -0.44; P = 0.001). We found no association between FGF19 and muscle thickness (P = 0.243).
We highlighted in older patients significant correlations between FGF19 levels, pennation angle and muscle fiber length, suggesting that FGF19 could provide an enabling environment for the development of large muscle fibers, as previously suggested in histological studies in mice. However, high FGF-19 levels were unexpectedly associated with a low SPPB score. Further studies are needed to validate and further elucidate these exploratory findings.
肌肉减少症具有重要的医学和经济影响。血清成纤维细胞生长因子 19(FGF19)最近被描述为促进肌肉质量和力量,并且可能是早期诊断肌肉减少症和预防其后果的一个有趣的标志物。超声是一种强大的非侵入性技术,用于测量肌肉参数,这些参数无法通过通常的身体成分测量来评估,但已知与肌肉功能相关。在这项横断面队列研究中,我们旨在确定 FGF19 水平是否与功能性肌肉测试和肌肉超声参数相关。
从“well on your feet”(保持独立行走)预防移动障碍计划的队列中招募了 70 岁以上有移动障碍风险的患者。根据欧洲老年人肌肉减少症工作组 2(EWGSOP2)标准诊断为肌肉减少症。我们进行了功能电池测试、肌肉超声测量和生物阻抗谱。FGF19 水平通过 ELISA 法测量。
在 52 名参与的患者中(34 名女性,平均年龄 81.3 岁),有 30 名患者患有肌肉减少症(15 名可能患有肌肉减少症,15 名患有明确的肌肉减少症)。肌肉减少症患者年龄较大(平均 82.8 岁与 79.6 岁,P=0.033),虚弱 Fried 评分较高(P=0.006),IADL 评分较低(P=0.008),每日蛋白质摄入量较低(P=0.023),且功能性肌肉测试表现不如非肌肉减少症患者。血清 FGF19 水平与 SPPB 评分呈负相关(r=0.28;P=0.045)。FGF19 水平与肌纤维角呈正相关(r=0.31;P=0.024),但与肌纤维长度呈负相关(r=-0.44;P=0.001)。我们未发现 FGF19 与肌肉厚度之间存在关联(P=0.243)。
我们在老年患者中发现 FGF19 水平与肌纤维角和肌纤维长度之间存在显著相关性,这表明 FGF19 可能为大肌肉纤维的发展提供有利的环境,正如之前在小鼠的组织学研究中所表明的那样。然而,出乎意料的是,高 FGF-19 水平与 SPPB 评分较低相关。需要进一步的研究来验证和进一步阐明这些探索性发现。